Skip to main content

Meet with our product experts in one-on-one virtual sessions

Set Up a Meeting
Quick Connect

White Paper

Tech Sheet - Dr. Reddy’s Ramipril API offerings

Ramipril is an angiotensin-converting enzyme (ACE) inhibitor indicated for treating hypertension to lower blood pressure. ACE inhibitors inhibit the angiotensin-converting enzyme (ACE) actions, thereby reducing the production of angiotensin II and decreasing the breakdown of bradykinin. The decrease in angiotensin II results in relaxation of arteriole smooth muscle leading to a reduction in total peripheral resistance, reducing blood pressure as the blood is pumped through widened vessels.

Ramipril works by lowering blood pressure and reducing the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. In addition, Ramipril, in combination with thiazide diuretics, is used to treat hypertension.

Dr. Reddy's is among the earliest generic API manufacturers globally to file the USDMF for Ramipril API. On October 4, 2000, the FDA approved the original dosage form, i.e., Altace® capsules, to reduce the risk of myocardial infarction, stroke, and cardiovascular diseases.

To know more about our API offerings, please read the technical sheet on Ramipril by filling the contact from below.

Explore other Whitepapers:

Know More

Download Now

Please fill the Contact form below in order to view the white paper


No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.

Checked out our

API Linkedin
page yet?

Follow this page to explore how our offerings can accelerate your formulation success

Click here to visit